FACCHETTI, FLORIANA
FACCHETTI, FLORIANA
Dipartimento di Fisiopatologia Medico-Chirurgica e dei Trapianti
Bulevirtide monotherapy for 48 weeks in patients with HDV-related compensated cirrhosis and clinically significant portal hypertension
2022 E. Degasperi, M. Anolli, S.C. UCEDA RENTERIA, D. Sambarino, M. Borghi, R. Perbellini, C. Scholtes, F. Facchetti, A. Loglio, S. Monico, M. Fraquelli, A. Costantino, F. Ceriotti, F. Zoulim, P. Lampertico
Circulating cell-free DNA species affect the risk of hepatocellular carcinoma in treated chronic hepatitis B patients
2021 A. Papatheodoridi, A. Chatzigeorgiou, L. Chrysavgis, P. Lembessis, A. Loglio, F. Facchetti, E. Cholongitas, M. Koutsilieris, P. Lampertico, G. Papatheodoridis
Application of EASL 2017 criteria for switching hepatitis B patients from tenofovir disoproxil to entecavir or tenofovir alafenamide
2020 L. Roade, A. Loglio, M. Borghi, M. Riveiro-Barciela, R. Soffredini, F. Facchetti, D. di Paolo, D. Tabernero, G. Lunghi, R. Esteban, M. Buti, P. Lampertico
The combination of PIVKA-II and AFP improves the detection accuracy for HCC in HBV caucasian cirrhotics on long-term oral therapy
2020 A. Loglio, M. Iavarone, F. Facchetti, D. Di Paolo, R. Perbellini, G. Lunghi, F. Ceriotti, C. Galli, M.T. Sandri, M. Vigano, A. Sangiovanni, M. Colombo, P. Lampertico
Hepatic fat - genetic risk score predicts hepatocellular carcinoma in HCV cirrhotic patients treated with DAAs
2020 E. Degasperi, E. Galmozzi, S. Pelusi, R. D'Ambrosio, R. Soffredini, M. Borghi, R. Perbellini, F. Facchetti, M. Iavarone, A. Sangiovanni, L. Valenti, P. Lampertico
Effectiveness and safety of switching to entecavir hepatitis B patients developing kidney dysfunction during tenofovir
2019 M. Vigano, A. Loglio, S. Labanca, S. Zaltron, F. Castelli, P. Andreone, V. Messina, R. Ganga, N. Coppola, A. Marrone, M. Russello, A. Marzano, A. Tucci, G. Taliani, M. Fasano, S. Fagiuoli, E. Villa, F. Bronte, T. Santantonio, G. Brancaccio, V. Occhipinti, F. Facchetti, G. Grossi, M. Rumi, P. Lampertico
Minimal increases of serum alpha-foetoprotein herald HCC detection in Caucasian HBV cirrhotic patients under long-term oral therapy
2019 A. Loglio, M. Iavarone, M. Vigano, A. Orenti, F. Facchetti, I. Cortinovis, G. Lunghi, F. Ceriotti, V. Occhipinti, M. Rumi, A. Sangiovanni, M. Colombo, P. Lampertico
Dose-adjusted EPOCH plus rituximab improves the clinical outcome of young patients affected by double expressor diffuse large B-cell lymphoma
2019 A. Dodero, A. Guidetti, A. Tucci, F. Barretta, M. Novo, L. Devizzi, A. Re, A. Passi, A. Pellegrinelli, G. Pruneri, R. Miceli, A. Testi, M. Pennisi, M.C. Di Chio, P. Matteucci, C. Carniti, F. Facchetti, G. Rossi, P. Corradini
Serum hepatitis B core-related antigen (HBcrAg) correlates with covalently closed circular DNA transcriptional activity in chronic hepatitis B patients
2019 B. Testoni, F. Lebossé, C. Scholtes, F. Berby, C. Miaglia, M. Subic, A. Loglio, F. Facchetti, P. Lampertico, M. Levrero, F. Zoulim
Introduction to histiocytic and dendritic cell neoplasms
2018 F. Facchetti, E. Berti, E.S. Jaffe, B. Zelger
Indeterminate cell histiocytosis/indeterminate dendritic cell tumour
2018 F. Facchetti, E. Berti, B. Zelger
IFNL4 rs368234815 and rs117648444 variants predict off-treatment HBsAg seroclearance in IFN-treated HBeAg-negative chronic hepatitis B patients
2018 E. Galmozzi, F. Facchetti, G. Glenda, A. Loglio, M. Vigano', L. Giovanna, M.G. Colombo, P. Lampertico
Lamivudine prophylaxis prevents hepatitis B virus reactivation in anti-HBc positive patients under rituximab for non-Hodgkin lymphoma
2018 A. Loglio, M. Viganò, G. Grossi, S. Labanca, M. Goldaniga, A. Pompa, L. Farina, M. Rumi, P. Corradini, F. Facchetti, G. Lunghi, L. Baldini, P. Lampertico
Erheim-Chester disease
2018 F. Facchetti, B. Zelger, E. Berti, E.S. Jaffe
Reticulohistiocytosis
2018 E. Berti, F. Facchetti, B. Zelger
Langerhans cell histiocytosis
2018 F. Facchetti, E. Berti
Tenofovir alafenamide as a rescue therapy in a patient with HBV-cirrhosis with a history of Fanconi syndrome and multidrug resistance
2018 G. Glenda, A. Loglio, F. Facchetti, B. Marta, R.M. Soffredini, E. Galmozzi, L. Giovanna, G. Anuj, P. Lampertico
TLR7 Agonist Increases Responses of Hepatitis B Virus–Specific T Cells and Natural Killer Cells in Patients With Chronic Hepatitis B Treated With Nucleos(T)Ide Analogues
2018 C. Boni, A. Vecchi, M. Rossi, D. Laccabue, T. Giuberti, A. Alfieri, P. Lampertico, G. Grossi, F. Facchetti, M.R. Brunetto, B. Coco, D. Cavallone, A. Mangia, R. Santoro, V. Piazzolla, A. Lau, A. Gaggar, G.M. Subramanian, C. Ferrari
Clinical features and outcomes of hepatocellular carcinoma in Caucasian cirrhotic patients on long-term analogue therapy for hepatitis B
2018 A. Loglio, M. Iavarone, G. Grossi, M. Viganò, M.G. Rumi, F. Facchetti, G. Lunghi, A. Sangiovanni, M. Colombo, P. Lampertico
Failure of long-term lamivudine prophylaxis in patients with resolved hepatitis B infection undergoing chemotherapy and allogenic hematopoietic stem cell transplantation for hematological malignancies : two case reports
2017 G. Grossi, M. Viganò, F. Facchetti, S. Labanca, A. Loglio, A. Dodero, V. Montefusco, P. Corradini, A. Cafro, R. Cairoli, M. Colombo, P. Lampertico